CN1060942C - Chinese herbal medicine for curing aplastic anemia - Google Patents

Chinese herbal medicine for curing aplastic anemia Download PDF

Info

Publication number
CN1060942C
CN1060942C CN95110058A CN95110058A CN1060942C CN 1060942 C CN1060942 C CN 1060942C CN 95110058 A CN95110058 A CN 95110058A CN 95110058 A CN95110058 A CN 95110058A CN 1060942 C CN1060942 C CN 1060942C
Authority
CN
China
Prior art keywords
medicine
fruit
mongolian medicine
root
aplastic anemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN95110058A
Other languages
Chinese (zh)
Other versions
CN1124652A (en
Inventor
邢鹤林
邢志阳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN95110058A priority Critical patent/CN1060942C/en
Publication of CN1124652A publication Critical patent/CN1124652A/en
Application granted granted Critical
Publication of CN1060942C publication Critical patent/CN1060942C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to a traditional Chinese medicine which is prepared from the following medicines of the proportion by weight: 4.13 of tsaoko fruit, 2.48 of gypsum, 2.48 of prairie milk vetch, 2.48 of momordica seed, 2.48 of small green tangerine peel, 2.48 of cardamom, 2.48 of Chinese eaglewood, 2.48 of india madder root, 2.48 of costus roots, 2.48 of ophiopogon root, 2.48 of trogopterus dung, 2.48 of lotus fruit, 2.48 of gardenia fruit, 2.48 of nardostachyos root and rhizome, 2.48 of medicine terminalia fruit, 2.48 of axillary choerospondias fruit, 2.48 of rosewood heart wood, 2.48 of dragon's blood, 0.83 of musk, 3.31 of xihua and 49.57 of sanxianhong. The mongolian medicine prepared maintains the natural medical speciality of medicines, and has the advantages of convenient administration, no side effect, definite curative effect, convenient outpatient medication and follow up medication, convenient administration for patients, easy bulk production and high utility value.

Description

The mongolian medicine that is used for the treatment of aplastic anemia
The present invention relates to a kind of mongolian medicine.
Aplastic anemia is one group of bone marrow stem cell and hematopoieticmicroenviron-ment damage of being caused by chemistry, physics, biology and unknown cause.So that red pulp is replaced by fatty marrow, pancytopenia in the blood, and the pernicious blood illness of hemopoietic function depletion, its acute about 90% is dead in 1 year, and chronic type can be survived for many years, but is bearing the misery that ordinary person is difficult to bear.In recent years, the diagnosis and treatment primary disease has been adopted androgen, 17-hydroxy-11-dehydrocorticosterone, therapy of combining Chinese and Western medicine, immunization therapy, splenectomy and bone marrow transplantation etc. both at home and abroad, the healing remission rate is increased, but still have the case about 70% to use above therapy can not obtain satisfactory effect.
The object of the present invention is to provide one group of mongolian medicine that is exclusively used in treatment aplastic anemia, this mongolian medicine is at different condition of illness, three kinds of prescriptions are made the ball shape, execute at three types of this disease and control, make treatment reach more definite effect, more economical practical purpose.
The objective of the invention is to finish by the following technical programs:
The percentage by weight of this mongolian medicine is:
Fructus Tsaoko 4.13; Gypsum Fibrosum, Herba Violae, Semen Momordicae, Radix Osyris Wightianae, Fructus Amomi Rotundus, Lignum Aquilariae Resinatum, Radix Rubiae, Radix Aucklandiae (Radix Vladimiriae), Radix Ophiopogonis, Oletum Trogopterori, SHILIANZI, Fructus Gardeniae, Radix Et Rhizoma Nardostachyos, Fructus Chebulae, Fructus Choerospondiatis, Lignum Dalbergiae Odoriferae, Sanguis Draxonis each 2.48; Moschus 0.83; Stigma Croci 3.31; Three flowers 49.57.
This mongolian medicine also can be prepared by following percentage by weight:
Lignum Aquilariae Resinatum, Lignum Dalbergiae Odoriferae, exhaust in vain, Fructus Amomi Rotundus, Flos Caryophylli, Semen Momordicae, Radix Et Rhizoma Nardostachyos, Radix Osyris Wightianae, must dial, Fructus Chebulae, Fructus Choerospondiatis, Radix Aucklandiae (Radix Vladimiriae), Punica granatum L., Fructus Crataegi, Fructus Hordei Germinatus each 1.7; Moschus 0.34; Semen Myristicae 1.13; Stigma Croci 2.25, Fructus Tsaoko 2.83; Three scarlet 67.95.
This mongolian medicine can also be prepared by following percentage by weight:
Calculus Bovis, Fel Ursi each 1.22; Moschus 2.44; Oletum Trogopterori, Stigma Croci, Fang Hai, Gypsum Fibrosum, Pan Baicao, HEIYUNXIANG, white Semen sojae atricolor each 4.88; Chang foretells, Fructus Choerospondiatis each 7.31; Radix Aucklandiae (Radix Vladimiriae) 9.74; Fructus Chebulae, Cornu Bubali powder, Radix Aconiti Kusnezoffii each 12.20.
Advantage of the present invention and effect are:
The present invention has inherited the outstanding legacy of Mongolian medicine's medicine, be suitable for the etiopathogenesis of Mongolian medicine's pharmacy theory and aplastic amenia,, adopted double-blind method through clinical practice and research more than 3 years, diagnosis and criterion of therapeutical effect by the unified regulation in the whole nation, testing result with science is a foundation, observes 405 routine case histories, and cure rate is 31.3%, total effective rate is 92.1%, especially this group sick (except that a routine head controls) all reaches this curative effect level with other therapies through controlling, so special value is arranged on the invalid basis.Date processing adopts statistical procedures and electronic computer stepwise regression analysis.The mongolian medicine preparation keeps the natural property of medicine.Taking convenience, have no side effect, but the determined curative effect outpatient service is with examining medication, make things convenient for patient, being easy to produce in batches, has very high practical value.
Below will the present invention is described in further detail by embodiment:
One, its preparation method is:
(1) select materials:
1. Moschus: when first-selected, by the pharmacopeia requirement to index identifications such as the true and false of Moschus, purity, temperature.Afterwards, be that whole choosing, purity reach more than 85% and can be used as medicine by provinces and cities' medicine inspection partial test again.
2. other each decoction pieces medicines: need to identify the true and false, quality, standard of every flavor medical herbs etc., must meet being used as medicine that pharmacopeia requires.
(2) standardization:
The key of pill preparation be blanking quantity, system operation and pill content etc. all can according to reach standardization and carry out preparation.
1. blanking quantity: to blanking people medicine, must adhere to that the above group of three people supervises jointly by outbound; Adhere to that pharmaceutical formulation is arranged, outbound, the complete documentation formality system of being used as medicine; Adhere to expensive thin medicine special managements such as Moschus.
2. pharmacy operation: preparation medicine mainly contains pulverizing, infiltration, stirring, refining ball, operations such as packing, each operation all have quantity, quality, time, successively, the requirement of standard such as form.
3. pill content: ball heavily is 5 grams, contains the standardization matters of various flavour of a drug quantity in every ball, and we follow the traditional compound method refining ball of mongolian medicine, as long as can strictly remove preparation by refining ball program and requirement, content and drug action just can be guaranteed in the ball.
(3) pulverize:
1. Moschus: with Moschus insert be ground in the mortar superfine standby.
2. other medical herbs of respectively distinguishing the flavor of: pulverize repeatedly through pulverizer, crossing 120 order medicated powder could be medicinal.
(4) preparation (pill):
1. refined honey: select the heating of high-quality honey for use, stir repeatedly, be advisable until no foam and moisture.
2. become to stick together: will refine good close and uniform powder and mix stirring, and stop mixing when reaching even, and place to become to stick together in 3-5 minute.
3. honeyed pill: be machined to honeyed pill with frustrating ball, ball heavily is 5 grams.
(5) Quality Control:
The honeyed pill quality control standard:
1. medicated powder must be 120 orders;
2. the pill color and luster is even, fine and smooth, smooth;
3. honeyed pill weight is 5 grams.
Two, function cures mainly:
Mongolian medicine's medicine is controlled executing of aplastic anemia, is to be raw material with the wholistic therapy, and it cures mainly and is:
(1) the spleen type becomes silted up purple sick (being insufficiency of the spleen property chronic aplastic anemia), based on the described prescription of claim 1;
(2) the liver type becomes silted up purple sick (being the deficiency of the liver chronic aplastic anemia), based on the described prescription of claim 2.
(3) platelet reduces disease (chronic aplastic anemia), based on the described prescription of claim 3.
Three, Therapeutic Method: method of administration is every day three times, each 1 ball, and water is obeyed it after meal.
Four, points for attention:
1. this medicine must leave lucifuge, cool place, dry local in;
2. hypertension, the careful usefulness of anemia of pregnant woman.
Now 405 examples of scientific research being observed case are analyzed;
One, source of data and method
1. case source: allly meet following condition person for being chosen as scientific research observation case.
(1) diagnosis is definite: learn inspection by General Hospital, Shenyang Military Command or city-level with the menses liquid of going to the hospital and make a definite diagnosis, more than three people of scientific research group, determine to diagnose by the unified diagnostic criteria in the whole nation.
(2) complete data: bone marrow examination and relevant hematological examination are arranged.
(3) long-term treatment can be adhered to, payment for medical care can be born.
(4) voluntary accepting Mongolian medicine medicine treatment is obeyed doctor's advice, and is signed voluntary contractor.
These 405 examples, wherein 8 examples are the inpatient, 397 examples are observed case history for outpatient service.
2. diagnostic criteria:
(1) pancytopenia, the reticulocyte absolute value reduces.
(2) generally there is not splenomegaly.
(3) bone marrow examination at least one position hypoplasia or severe lower (must have megalokaryocyte obviously to reduce as active proliferation, should see that non-hematopoietic cell increases in the bone marrow granule composition).
(4) other causes the pathological changes of pancytopenia except the energy.
(5) general anti-anemic drug thing is failed to respond to any medical treatment.
3. criterion of therapeutical effect:
(1) the basic healing: the hemorrhage disappearance of anemia, hemoglobin male 120g/L, women 100g/L, leukocyte 4 * 10 9/ L, platelet 80 * 10 9/ L follows up a case by regular visits to and does not have recurrence more than 1 year.
(2) alleviate: anemia, hemorrhage disappearance, hemoglobin male 120g/L, women 100g/L, leukocyte 3.5 * 10 9/ L platelet has recovery to a certain degree.Follow up a case by regular visits to three months stable disease or continue progress person.
(3) obviously progressive: anemia, hemorrhage being clearly better, not transfuse blood, the modal value that hemoglobin was treated previous month increases 30g/L, keeps and does not fall in three months.
Judge that above three criterions of therapeutical effect all should not transfuse blood in three months.
(4) invalid: the symptom hemogram can not reach obvious progressive person after fully treating.
This group case adopts collective of seminar to appraise method through discussion, participates in evaluation by above standard at least 4 people, and myelosis type aplastic anemia is carried out special assessment.
4. Therapeutic Method: whole all oral mongolian medicines of case, be interrupted blood donor's 37 examples simultaneously.
The mongolian medicine input is carried out differentiation of symptoms and signs for classification of syndrome according to Mongolian medicine's theory.
5. the method for inspection: before treatment, do hemogram, bone marrow smear and other relevant required project of Differential Diagnosis, each moon of treatment back is hemogram checking 1-4 time, and assay is carried out standardization, detects hemoglobin value (Ku Erte blood counting instrument) person as adopting the ferric sesquichloride method.Then standardized value is the Hb value - ( 2 + 3 ) 2 。Efficacy determination carries out statistical analysis to be decision content with treatment back the last time with the last hemogram in treatment back once before treating.
Two, ordinary circumstance
In 405 examples, male's 258 examples account for 63.7, and women's 147 examples account for 36.3%, and men and women's ratio is 1.75: 1.Minimum 3 years old of age, maximum 76 years old.The course of disease is the shortest 1 month, and is the longest 35 years, median 1-2.Promptly toward through western medicine 162 examples, bone marrow transplantation fail 2 examples, cut recurrence 1 example behind the spleen, through Chinese and western medicine therapist 239 examples in succession or simultaneously.Head example 1 example of curing the disease, non-head example 404 examples of curing the disease.
Three, efficacy analysis: cure 65 examples substantially, account for 16.0%; Alleviate 62 examples, account for 15.0%; Obviously progressive 105 examples account for 26.0%; Invalid 173 examples account for 42.7%.The basic healing and remission rate 31.3%.For ease of carrying out reference with national constituent parts, the special clinical hematology of pressing.
Ordered canonical statistics is as follows: cure 65 examples substantially, account for 16.0%; Alleviate 62 examples, account for 15.3%; Obviously progressive 105 examples account for 26.0%; Stablize 141 examples, account for 34.8%; Invalid 32 examples account for 7.9%, total effective rate 92.1%.
The checking of clinical efficacy:
One, checking content (index):
Following up a case by regular visits to checking content index mainly contains:
1. accept Mongolian medicine's medicine treatment front and back situation: as diagnosis and the treatment situation before the usefulness mongolian medicine; With change of illness state behind the mongolian medicine; During with mongolian medicine, whether adopt other therapies etc.
2. observe patient's present situation; As dietetic life, the mental status, sign performance, anemia, hemorrhage, infectious fever and study and work situation etc.
3. recent hemogram and bone marrow smear result.
Two, verification method:
1. stochastic sampling is selected case:
Because time and funds are limit, from the close-by examples to those far off to determine in Jilin after deliberation, Liaoning, Hebei, Shandong Si Sheng, the scientific research case of Inner Mongol autonomous region and Beijing, two municipalities directly under the Central Government in Tianjin is the scope of following up a case by regular visits to.Mongolian medicine's medicine institute provides the overall case in this scope, and patient conveniently visits by random demand in group.
See " the associating stochastic sampling is followed up a case by regular visits to part scientific research case registration form ".
The associating stochastic sampling is followed up a case by regular visits to part scientific research case registration form
Figure 9511005800081
The associating stochastic sampling is followed up a case by regular visits to part scientific research case registration form
Figure 9511005800091
The associating stochastic sampling is followed up a case by regular visits to part scientific research case registration form

Claims (1)

1. the mongolian medicine that is used for the treatment of aplastic anemia is characterized in that this mongolian medicine each component and percentage by weight thereof are:
Calculus Bovis, Fel Ursi each 1.22; Moschus 2.44; Oletum Trogopterori, Stigma Croci, Fang Hai, Gypsum Fibrosum, Pan Baicao, HEIYUNXIANG, white Semen sojae atricolor each 4.88; Chang foretells, Fructus Choerospondiatis each 7.31; Radix Aucklandiae (Radix Vladimiriae) 9.74; Fructus Chebulae, Cornu Bubali powder, Radix Aconiti Kusnezoffii each 12.20.
CN95110058A 1995-02-23 1995-02-23 Chinese herbal medicine for curing aplastic anemia Expired - Fee Related CN1060942C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN95110058A CN1060942C (en) 1995-02-23 1995-02-23 Chinese herbal medicine for curing aplastic anemia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN95110058A CN1060942C (en) 1995-02-23 1995-02-23 Chinese herbal medicine for curing aplastic anemia

Publications (2)

Publication Number Publication Date
CN1124652A CN1124652A (en) 1996-06-19
CN1060942C true CN1060942C (en) 2001-01-24

Family

ID=5077484

Family Applications (1)

Application Number Title Priority Date Filing Date
CN95110058A Expired - Fee Related CN1060942C (en) 1995-02-23 1995-02-23 Chinese herbal medicine for curing aplastic anemia

Country Status (1)

Country Link
CN (1) CN1060942C (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100463692C (en) * 2004-06-24 2009-02-25 邢鹤林 Bone marrow benefiting capsule for treating anemia
CN106039197A (en) * 2016-07-28 2016-10-26 辽宁省阜新蒙医药研究所 Tsaoko amomum fruit twenty-first-flavor pill and identification method thereof
CN106389764B (en) * 2016-09-23 2019-10-08 浙江省中医院 A kind of Chinese materia medica preparation and its preparation and application

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1032903A (en) * 1987-11-06 1989-05-17 齐向春 Synthesized therapeutic mineral water mud, powder processing method
CN1051504A (en) * 1989-11-04 1991-05-22 姜振轩 The compound method and the technology of regeneration powder
CN1058530A (en) * 1990-08-02 1992-02-12 鞍山钢铁公司 Artificially synthetic mineralized powder
CN1067374A (en) * 1992-05-09 1992-12-30 宫锡和 Hot spring powder and application thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1032903A (en) * 1987-11-06 1989-05-17 齐向春 Synthesized therapeutic mineral water mud, powder processing method
CN1051504A (en) * 1989-11-04 1991-05-22 姜振轩 The compound method and the technology of regeneration powder
CN1058530A (en) * 1990-08-02 1992-02-12 鞍山钢铁公司 Artificially synthetic mineralized powder
CN1067374A (en) * 1992-05-09 1992-12-30 宫锡和 Hot spring powder and application thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
《中药材》1987年第3期 1987.1.1 白明纲,蒙药广枣 *
《中西医结合杂志》1990年第10卷第1期 1990.1.1 王镜等,中药为主治疗再生障碍性贫血78例 *
《海洋药物杂志》1983年第1期 1983.1.1 马万哲,方海的生药学研究 *
《海洋药物杂志》1983年第1期 1983.1.1 马万哲,方海的生药学研究;《中西医结合杂志》1990年第10卷第1期 1990.1.1 王镜等,中药为主治疗再生障碍性贫血78例;《中药材》1987年第3期 1987.1.1 白明纲,蒙药广枣 *

Also Published As

Publication number Publication date
CN1124652A (en) 1996-06-19

Similar Documents

Publication Publication Date Title
CN1044974C (en) Anti- hepatitis B preparation
CN1113778A (en) Preparation for treating senile diseases
CN1092981C (en) Medicine for curing arthralgia-syndrome resulted from wind,cold and dampness and its preparation method
CN1060942C (en) Chinese herbal medicine for curing aplastic anemia
CN1250264C (en) Capsule for curing hyperplasia of mammary glands and its preparation method
CN1046421C (en) Drug for curing pulmonary tuberculosis
CN101028325A (en) Medicinal composition containing sailonggu, and its preparation and quality control
CN1289115C (en) Immunity raising Chinese medicine and its prepn process
CN1857561A (en) Osteoporosis treating medicine and its preparing method
CN1425395A (en) Bolus for eliminating arthralgia and activating energy flow in channels and collaterals and its preparing method
CN1176689C (en) Medicine for treating primary dysmenorrhea and its prepn
CN1283287C (en) Pharmaceutical composition for treating climacteric syndrome and its preparing process
CN1422628A (en) Baixue-Genzhi-Changshoubao-Chinese medicine for treating leukemia and concurrently treating aplastic anemia
CN1056071C (en) Hepatitis virus inhibitor and prepn. method thereof
CN1065755C (en) Chinese compound medicine for treatment of hepatic calculus and cholecystitis
CN1186036C (en) Diabetes treating medicine and its prepn
CN1059590C (en) Medicine for blood generation and preparing method
CN1109552C (en) Capsule for treating enteritis
CN1233359C (en) Compound Jigucao capsule (Abrus fruticulosus Wall. ex Wight et Arn.) and its prodn. method
CN101632818B (en) Traditional Chinese medicine medicinal powder for treating diabetes and preparation method thereof
CN118320044A (en) Traditional Chinese medicine composition for treating chronic mountain sickness and preparation method thereof
CN1060677C (en) Preparation for senile disease
CN1131058C (en) Chinese medicine for treating blood viscosity and its preparing process
CN1147313C (en) Orally applied medicine 'Gukangwang' for treating arthropathy and its preparing process
CN100339017C (en) Linghe tea

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee